Technique enables efficient gene splicing in human embryonic stem cells

p>CAMBRIDGE, Mass. (August 13, 2009) — A novel technique allows researchers to efficiently and precisely modify or introduce genes into the genomes of human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, according to Whitehead scientists. The method uses proteins called zinc finger nucleases and is described in the August 13 issue of Nature Biotechnology.

For years, scientists have easily swapped genes in and out of mouse ESC or iPS cell genomes, but have had a notoriously difficult time disrupting or inserting genes into their human equivalents.

“It’s not clear where this hurdle of genetic manipulation lies; it could be purely technical, but it could also be an inherent difference between human and mouse cells,” says Dirk Hockemeyer. Hockemeyer and Frank Soldner are first authors on the article and postdoctoral researchers in Whitehead Member Rudolf Jaensich’s lab. “Other people have genetically manipulated these human cells, but the process has been extremely laborious and extremely time consuming. Using the zinc finger nucleases makes the process very easy,” says Hockemeyer.

Earlier methods are so inefficient that fewer than 15 genes have been swapped into human ESCs since that cell type was discovered 10 years ago. By comparison, hundreds of genes have been introduced into the genomes of mouse ESCs.

According to Jaenisch, this method could open a new phase in human genetics.

“This is a proof of principle that zinc finger nucleases can be used to swap out many, many additional genes in human ESCs and iPS cells,” says Jaenisch, who is also a professor of biology at MIT. “Now human ESC and iPS cell genetics can catch up to mouse genetics, which has had a 20-year headstart.”

The inability to alter human ESC and iPS cells’ genomes has hindered researchers from routinely creating specific cell types for modeling genetic diseases (e.g., the brain cells affected by Parkinsons’s disease) and studying how embryonic stem cells mature into adult cells. (iPS cells are adult cells that have been reprogrammed to an embryonic-stem-cell-like state, so they have similar properties of ESCs: the ability to self-propagate and the ability to mature into any of an adult’s approximately 220 cell types. iPS cells have the added benefit of possessing the same genes as the patient who donated the adult cells, thereby accurately reflecting that patient’s specific genetic profile.)

To substitute a gene in ESCs and iPS cells, Hockemeyer and Soldner adapted a recently developed technique to cut out one gene from the human ESCs and iPS cells and substitute it with another by putting two zinc finger nucleases and the replacement gene into the ESCs and iPS cells.

Each zinc finger nuclease recognizes a particular sequence in a cell’s DNA and then cuts through both strands of DNA at that site. The cell’s DNA repair machinery recognizes that the DNA has been cut and tries to fix it using the replacement gene resulting in the desired alteration of the original gene.

In addition to working so efficiently, the method can be tailored to precisely swap nearly any gene in the genome.

“We can produce zinc finger nucleases that out of about three billion DNA base pairs can identify one specific site,” says Soldner. “We also spent quite a bit of energy to see if the zinc finger nucleases cut somewhere other than the intended target site, and it was very unlikely.”

The research was conducted in collaboration with Sangamo BioSciences, Inc., which designed and produced the zinc finger nucleases.

The National Institutes of Health (NIH) and the Life Sciences Research Foundation provided funding for this research.

Rudolf Jaenisch’s primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.

Full Citation:

“Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases”

Dirk Hockemeyer (1*), Frank Soldner (1*), Caroline Beard (1), Qing Gao (1), Maisam Mitalipova (1), Russell C. DeKelver (3), George E. Katibah (3), Ranier Amora (3), Elizabeth A. Boydston (3), Bryan Zeitler (3), Xiangdong Meng (3), Jeffrey C. Miller (3), Lei Zhang (3), Edward J. Rebar (3), Philip D. Gregory (3), Fyodor D. Urnov (3), and Rudolf Jaenisch (1,2)

1. The Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, 02142 MA, USA

2. Department of Biology, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139, USA

3. Sangamo BioSciences, Inc., Pt. Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, CA 94804, USA

* These authors contributed equally to this work

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.